8-K ·Filed Jun 8, 2026

CELC

Celcuity Inc.
MIXED
Impact 6/10
Horizonweeks Processed3mo ago SEC0001493152-26-027717
8-K material event: Items 1.01, 1.02
Actionable Insight ◆ Mixed

The debt-for-debt refinancing (secured to unsecured) and extended cash runway through 2028 are credit-positive for preferred holders. Monitor the stock price relative to the $124.53 conversion threshold — sustained trading above may trigger conversion and dilute common equity, which would be neutral for the preferred. The large total convertible balance (~$701M) could pressure the common if the stock rallies significantly, but preferred dividend coverage improves with the term loan repayment.

DirectionMixed
Confidencehigh
Horizonweeks
Final — all horizons settled through T+60d
CELC ▲ +3.90% at T+60d
NEUTRAL call ✓ call won +3.90% · α vs SPY +0.09% · entry $92.59 → $96.20
Entry anchored
Jun 8, 03:59 PM ET
via exchange tick
T+1d
-4.70%
call -4.70% · α -3.12%
$88.24
settled 4mo ago
T+5d
-4.70%
call -4.70% · α -7.11%
$88.24
settled 4mo ago
T+20d
+24.98%
call +24.98% · α +23.53%
$115.72
settled 3mo ago
T+60d
+3.90%
call +3.90% · α +0.09%
$96.20
settled 4w ago

Price Chart

Loading chart...

Executive Summary

Celcuity closed a $500M (plus $75M over-allotment) 0.250% convertible senior notes offering on June 8, 2026, executing the second supplemental indenture and underwriting agreement filed as exhibits to this 8-K. Net proceeds of ~$484.3M will repay the $137.9M secured term loan (de-levering to zero secured debt) and fund working capital, commercial launch, and pipeline through 2028. This follows preliminary filings from June 3 and June 5; the combination of large unsecured convert issuance (~$701M in total converts including prior tranches) with secured debt repayment is credit-positive for the capital structure but adds substantial leverage and potential dilution.

Key Facts

  • $575M total (initial $500M + $75M over-allotment) of 0.250% convertible senior notes due 2032 issued
  • Initial conversion rate of 8.0302 shares per $1,000 principal, equal to ~$124.53 conversion price
  • Initial conversion premium was 57.2% above the $79.23 stock price (based on preliminary pricing; final terms confirmed in indenture)
  • Net proceeds of ~$484.3M will fully repay the $137.9M secured term loan and fund clinical/commercial pipeline
  • The de-levering to $0 secured debt is a significant credit event for the preferred equity structure
  • Aggregate convertible debt now totals ~$701M ($201M prior + $575M new), adding material leverage and potential stock dilution
  • Underwriters purchased at 97.0% of principal; Jefferies, J.P. Morgan, TD Cowen, Guggenheim led the syndicate

Financial Impact

Deleveraging of $137.9M secured term loan (~$484.3M net proceeds) is positive credit event, but raises total convertible debt to ~$701M (potential for substantial dilution if converted; initial conversion rate implies 4.62M shares on base of ~28M outstanding at the $124.53 conversion price plus make-whole adjustments up to 11.2422 shares per $1,000 = ~6.46M shares fully diluted).

debtdilutioncapital_structurecash_runway

Risk Factors

  • ~$701M in total convertible debt creates significant potential common stock dilution if conversion threshold is met
  • Reliance on capital markets for future financing needs; large unsecured convert exposes balance sheet to conversion risk
  • Execution risk in commercial launch and pipeline development given funds deployment timeline

Market Snapshot

Exchange
Nasdaq
Sector
Services-Medical Laboratories
Analyst Consensus
94% bullish (18 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 2 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001493152-26-027717
Exhibit: ex1-1.htm0001493152-26-027717
15 reports for CELC
Performance horizon
89% Hit rate 8 of 9 directional calls best @ T+20▲ +26.84%Jun 11, 2026
Filters
Rows
Reports for CELC — sortable, filterable
TypeNow
Aug 26, 2026
5w ago
8-K
BULLISH ★ 7/10
$95.08 $84.00▼ −11.65%▼ −12.86%$72.51 (−23.74%)
Jul 15, 2026
11w ago
144
BEARISH ★ 6/10
$91.51 $92.08▼ −0.62%▲ +1.72%$72.51 (+20.76%)
Jul 14, 2026
11w ago
Press Release
BULLISH ★ 8/10
$91.51 $92.08▲ +0.62%▼ −1.72%$72.51 (−20.76%)
Jun 11, 2026
16w ago
Institutional Cluster
BULLISH ★ 5/10
$89.49 $113.51▲ +26.84%▲ +24.95%$72.51 (−18.97%)
Jun 8, 2026
16w ago
8-K
MIXED ★ 6/10
$92.59 $115.72▲ +24.98%▲ +23.53%$72.51 (−21.69%)
Jun 5, 2026
17w ago
424B5
MIXED ★ 6/10
$88.28 $108.58▲ +23.00%▲ +21.13%$72.51 (−17.86%)
Jun 4, 2026
17w ago
Press Release
MIXED ★ 6/10
$92.47 $107.95▲ +16.74%▲ +18.11%$72.51 (−21.59%)
Jun 3, 2026
17w ago
Press Release
BEARISH ★ 6/10
$88.95 $107.95▼ −21.36%▼ −22.36%$72.51 (+18.48%)
Jun 3, 2026
17w ago
424B5
BEARISH ★ 6/10
$88.95 $107.95▼ −21.36%▼ −22.36%$72.51 (+18.48%)
Jun 2, 2026
17w ago
8-K
BULLISH ★ 8/10
$91.42 $104.49▲ +14.30%▲ +15.86%$72.51 (−20.68%)
Showing 10 of 15

US Market Status

Market Open — Closes in 2h 13m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access